title: Letter to the Editor on Pastores et al. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
authors.affiliation: Vice President and Head of Integrated Solutions, Rare Diseases, Sanofi Genzyme, Genzyme Center, 500 Kendall Street, Cambridge, MA 02142, United States. Electronic address: Joan.Keutzer@genzyme.com.
authors.forename: Joan
authors.initials: J
authors.lastname: Keutzer
authors.affiliation: Vice President and Head of Global Medical Affairs, Rare Diseases, Sanofi Genzyme, United States.
authors.forename: Daniel
authors.initials: D
authors.lastname: Gruskin
mesh_terms: D056947:Enzyme Replacement Therapy; D005776:Gaucher Disease; D005962:Glucosylceramidase; D006801:Humans
chemical_list: D005962:Glucosylceramidase